{"id":11048,"date":"2020-10-21T11:39:00","date_gmt":"2020-10-21T15:39:00","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11048"},"modified":"2026-10-28T14:04:24","modified_gmt":"2026-10-28T18:04:24","slug":"nia-announces-new-stock-suggestion-rvv","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/nia-announces-new-stock-suggestion-rvv\/","title":{"rendered":"NIA Announces New Stock Suggestion: RVV"},"content":{"rendered":"\n

NIA is excited<\/strong><\/span> to announce its new #1 favorite psychedelic <\/span>biotechnology stock suggestion<\/strong>: Revive Therapeutics (CSE: RVV)<\/strong> with a U.S. OTC<\/strong> symbol: RVVTF<\/strong>. In recent months, the COVID-19 pandemic<\/strong><\/span> has caused\u00a0methamphetamine use disorder <\/strong><\/span>to spiral out of control<\/strong><\/span><\/em> across North America. Yesterday, AP News<\/strong> published an article<\/strong><\/a> entitled, ‘US overdose deaths<\/span> appear to rise<\/span> amid coronavirus pandemic<\/span>‘<\/strong>. It discusses how\u00a0new CDC data confirms<\/span><\/strong> that COVID-19<\/strong><\/span> is exacerbating<\/strong><\/em><\/span> the U.S.<\/strong> overdose crisis<\/strong><\/span> – with\u00a0methamphetamine<\/strong> <\/span>and fentanyl<\/strong><\/span> causing most <\/span>overdose deaths<\/span><\/strong>.<\/span><\/span><\/p>\n

The need to find effective treatments<\/strong><\/span> for methamphetamine dependence<\/strong><\/span> has been identified as a priority<\/strong><\/span> by the United States National Institute on Drug Abuse (NIDA)<\/strong> and by European investigators<\/strong>.\u00a0There are currently no<\/span> drugs approved<\/span><\/strong> for helping treat<\/span> methamphetamine addiction<\/span><\/strong>.<\/span><\/span><\/p>\n

RVV<\/strong> owns valuable<\/span> intellectual property<\/strong> related to psilocybin<\/strong> and other psychedelics<\/strong> including its patent-pending<\/span> oral thin-film delivery system<\/strong> for psilocybin<\/strong>, which offers a unique delivery platform<\/strong><\/span> for therapeutic doses<\/strong> of psilocybin<\/strong> into the oral cavity<\/strong>. RVV<\/strong> has received its final<\/span> set<\/strong> of prototypes <\/strong>and is preparing to scale<\/span> manufacturing<\/strong> for future clinical studies<\/strong> involving psilocybin<\/strong> and other psychedelic-derived medicines<\/strong>.<\/span><\/span><\/p>\n

RVV’s orally dissolvable psilocybin thin-film<\/strong> will not only allow<\/span> doctors<\/strong> to prescribe exact<\/span> dosages<\/strong> of psilocybin<\/strong> ranging from 1mg up to<\/span> 20mg<\/strong>, but it will make psilocybin much easier<\/span><\/strong> to consume<\/span> without<\/span><\/strong> the need of water<\/strong>, chewing<\/strong> or swallowing<\/strong> \u2013 while allowing it to enter<\/strong><\/span> the bloodstream<\/strong><\/span> much faster<\/strong><\/span>. Psilocybin mushrooms<\/strong> are extremely difficult<\/strong><\/span> to chew<\/strong> and swallow<\/strong> and their effects<\/strong><\/span> usually don’t<\/strong><\/span> kick in<\/strong><\/span> until up to<\/span> one hour <\/strong>later. RVV<\/strong> has what we consider to be the industry’s #1 solution<\/strong><\/span> to these issues<\/strong><\/span>! Click here<\/a> to see a list of RVV’s provisional patents filed!<\/em><\/strong><\/span><\/span><\/p>\n

RVV<\/strong> has entered into<\/strong><\/span> a Clinical Trial Agreement<\/strong> with the Board of Regents<\/strong> of the University of Wisconsin System<\/strong> to conduct<\/strong><\/span> a clinical study<\/strong> entitled \u201cPhase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder<\/span>.\u201d<\/strong> The clinical study<\/strong> will be conducted<\/strong><\/span> at the University of Wisconsin\u2012Madison School of Medicine and Public Health<\/strong> and the UW\u2013Madison School of Pharmacy<\/strong>, which holds a Wisconsin special authorization<\/span><\/strong> and DEA license<\/span><\/strong> to perform clinical research<\/strong> with psilocybin<\/strong>.<\/span><\/span><\/p>\n

RVV<\/strong> has also signed<\/strong><\/span> a supply agreement<\/strong> with Havn Life Sciences<\/strong> to source naturally-derived<\/span> psychedelic compounds<\/strong>, such as psilocybin<\/strong>, for use in future Investigational New Drug (IND) enabling<\/span> studies<\/strong> and clinical trials<\/strong> under Food and Drug Administration (FDA) guidelines<\/strong>. Methamphetamine<\/strong> kills<\/span> thousands<\/strong> of Americans each year and we believe RVV’s psilocybin thin-film <\/strong>could have potential to one day become a major part of the industry standard for treating<\/strong><\/span> methamphetamine<\/span> addiction<\/span><\/strong>!<\/span><\/span><\/p>\n

RVV<\/strong> is also in the process of conducting<\/span> Phase 3 clinical trials<\/strong> for a major<\/span> COVID-19 treatment<\/span><\/strong> that we believe is giving RVV<\/strong> most of its current market cap<\/strong>. In our opinion, RVV<\/strong> is not yet<\/strong><\/span> being valued<\/strong><\/span> as a psychedelic play<\/strong> that is positioned to capitalize<\/strong><\/span> on the upcoming surge in interest<\/strong><\/span> in psilocybin<\/strong> that will occur as a result of the November 3rd ballot initiatives<\/span><\/strong> in Oregon and Washington DC.<\/span><\/span><\/p>\n

You can visit the FDA’s web site<\/strong> by going to: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04504734<\/a><\/strong> and it will tell you all about RVV’s ‘Bucillamine in Treatment of Patients With COVID-19’<\/strong>. This is a Randomized<\/strong>, Double-blind<\/strong>, placebo controlled trial<\/strong> with up to<\/span> 1,000 patients<\/strong>. RVV<\/strong> at its current price of $0.245 per share<\/strong> with 236,790,599 shares outstanding has a market cap<\/strong> of only USD$44.22 million<\/strong><\/span>.<\/span><\/span><\/p>\n

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has been compensated by RVV USD$30,000 cash and expects to receive 200,000 restricted common shares of RVV stock for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.<\/em><\/span><\/span><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

NIA is excited to announce its new #1 favorite psychedelic biotechnology stock suggestion: Revive Therapeutics (CSE: RVV) with a U.S. OTC symbol: RVVTF. In recent months, the COVID-19 pandemic has caused\u00a0methamphetamine use disorder to spiral out of control across North America. Yesterday, AP News published an article entitled, ‘US overdose deaths appear to rise amid […]<\/p>\n","protected":false},"author":1,"featured_media":11049,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,311],"class_list":["post-11048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-rvv"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11048"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11048\/revisions"}],"predecessor-version":[{"id":11050,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11048\/revisions\/11050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11049"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}